COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City.
COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City.
复制标题
DOI：
10.1016/j.clim.2021.108803
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Cunningham-Rundles C
中科院分区：
文献类型：
--
作者：
Harada K;Ho HE;Cunningham-Rundles C
为了更好地了解接受生物和免疫调节治疗的患者中的COVID-19感染，我们评估了大流行高峰期间纽约市一家大型治疗输液中心的COVID-19症状病例的患病率和结局。2020年3月至5月期间，2074名患者在我中心接受了生物输注治疗，34名患者出现了症状性COVID-19感染，总体发生率较低，为1. 64%。大多数感染和死亡发生在一小部分原发性免疫缺陷患者中。需要生物治疗的炎症或自身免疫性疾病患者倾向于轻度病例。在死亡的患者中观察到更高的炎症反应。
To better understand COVID-19 infection in patients receiving biologic and immunomodulatory therapies, we evaluated prevalence and outcomes for symptomatic cases of COVID-19 at a large therapeutic infusion center in New York City during the height of the pandemic. 2074 patients received treatment with biologic infusions at our center between March and May 2020, and 34 patients developed symptomatic COVID-19 infection, for an overall low rate of 1.64%. The majority of infections and deaths were in a small subset of patients with a primary immunodeficiency. Patients with inflammatory or autoimmune conditions requiring biologic therapies tended to have mild cases. Higher inflammatory responses were observed in patients who died.
登录
查看更多内容
影响因子：
5.8
作者：
Loonstra, Floor C.;Hoitsma, Elske;Mostert, Jop P.
通讯作者：
Mostert, Jop P.
影响因子：
4.9
作者：
Axelrad, Jordan E.;Malter, Lisa;Hudesman, David
通讯作者：
Hudesman, David
影响因子：
7.3
作者：
Bhaskar, Sonu;Sinha, Akansha;Kutty, Shelby
通讯作者：
Kutty, Shelby
影响因子：
82.9
作者：
Del Valle DM;Kim-Schulze S;Huang HH;Beckmann ND;Nirenberg S;Wang B;Lavin Y;Swartz TH;Madduri D;Stock A;Marron TU;Xie H;Patel M;Tuballes K;Van Oekelen O;Rahman A;Kovatch P;Aberg JA;Schadt E;Jagannath S;Mazumdar M;Charney AW;Firpo-Betancourt A;Mendu DR;Jhang J;Reich D;Sigel K;Cordon-Cardo C;Feldmann M;Parekh S;Merad M;Gnjatic S
通讯作者：
Gnjatic S
影响因子：
100.3
作者：
Merad, Miriam;Martin, Jerome C.
通讯作者：
Martin, Jerome C.